FDG PET-CT in Metastatic Prostate Cancer

FDG PET-CT 在转移性前列腺癌中的应用

• 批准号: 7111104
• 负责人: HOSSEIN JADVAR
• 金额: $ 50.06万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-12 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7111104
• 关键词: androgens; bioimaging /biomedical imaging; clinical research; deoxyglucose; diagnosis design /evaluation; diagnosis quality /standard; glucose metabolism; hormone therapy; human subject; human therapy evaluation; metastasis; neoplasm /cancer diagnosis; neoplasm /cancer therapy; patient oriented research; positron emission tomography; prognosis; prostate neoplasms; questionnaires; statistics /biometry

DESCRIPTION (provided by applicant): Prostate cancer will become an epidemic male health problem due to increasing life expectancy. There is a critical need for accurate imaging evaluation of patients with metastatic prostate cancer. Positron emission tomography (PET) with the most common tracer currently available, [F-18]-fluorodeoxyglucose (FDG), has emerged as an important diagnostic imaging modality in cancer. Recent advances in imaging technology have also resulted in dual-modality PET-CT systems that allow precise fusion of anatomic and metabolic imaging data. Our preliminary in-vitro cell culture, animal in-vivo, and pilot clinical studies have provided compelling evidence that FDG PET may have a significant role in the imaging evaluation of patients with metastatic prostate cancer. There are two specific aims for this research proposal: 1) to assess the diagnostic utility of FDG PET-CT in the evaluation of therapy response in two clinically distinct groups of patients with metastatic prostate cancer, Group I: men with newly diagnosed hormone-naive metastatic disease who will be treated with the standard androgen ablation therapy, and Group II: men with newly developed hormone-refractory metastatic cancer who will be treated with standard chemotherapy, and 2) to evaluate FDG PET-CT in predicting patient outcome. We hypothesize that semi-quantitative FDG PET-CT monitoring of the serial changes in the glucose metabolism of metastatic prostate cancer lesions provides a competitive advantage over the conventional methods in the objective assessment of treatment response and in predicting key clinical outcomes. To test this hypothesis, we will perform a prospective cohort study to evaluate the diagnostic and prognostic utility of serial FDG PET-CT imaging in determining tumor metabolic response to either androgen ablation therapy or to chemotherapy and in predicting key clinical outcomes such as time to hormone-refractory state and survival. Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting.

描述（由申请人提供）：由于预期寿命的增加，前列腺癌将成为流行病的男性健康问题。非常需要对转移性前列腺癌患者进行准确的成像评估。当前最常见的示踪剂[F-18] -Fluordeoxyglucose（FDG）的正电子发射断层扫描（PET）已成为癌症中重要的诊断成像方式。成像技术的最新进展也导致了双模式PET-CT系统，这些系统允许精确融合解剖和代谢成像数据。我们的初步体外细胞培养，动物体内和初步临床研究提供了令人信服的证据，表明FDG PET在对转移性前列腺癌患者的成像评估中可能具有重要作用。 There are two specific aims for this research proposal: 1) to assess the diagnostic utility of FDG PET-CT in the evaluation of therapy response in two clinically distinct groups of patients with metastatic prostate cancer, Group I: men with newly diagnosed hormone-naive metastatic disease who will be treated with the standard androgen ablation therapy, and Group II: men with newly developed hormone-refractory metastatic cancer who will be treated with standard化学疗法和2）评估FDG PET-CT在预测患者预后。我们假设对转移性前列腺癌病变的葡萄糖代谢的串行变化的半定量FDG PET-CT监测在治疗反应的客观评估和预测关键临床结果方面为常规方法提供了竞争优势。为了检验这一假设，我们将进行一项前瞻性队列研究，以评估串行FDG PET-CT成像的诊断和预后效用，以确定对雄激素消融疗法或化学疗法的肿瘤代谢反应，以及预测关键的临床临床结果，例如对激素 - 恢复差异和生存的时间。在这种临床环境中，将采用严格的统计方法来确定FDG PET-CT的诊断和预后性能。